News and Announcements
Phylogica and Bio-Link Collaborate to Commercialise Anti-Inflammatory Phylomers
- Published February 05, 2013 9:14AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: February 05, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has entered an agreement with Bio-Link Australia Pty. Ltd., a specialist life sciences business development company, to commercialise a family of anti-inflammatory PhylomerÒ peptides for pharmaceutical use. Under the terms of the agreement, Bio-Link will work with Phylogica to monetize these assets through out-licensing or disposal of the Phylomer peptides to a pharmaceutical or biotechnology company.
To read full announcement, please download the document below.